Actinium Pharmac Stock Price, News & Analysis

Actinium Pharmaceuticals (ATNM) showcased its pivotal Phase 3 SIERRA trial for Iomab-B at the 2021 TCT Annual Meeting, highlighting significant progress in targeted conditioning for bone marrow transplants. Key findings include a 100% BMT rate for Iomab-B patients versus 18% for conventional therapy. Additionally, 79% of patients in the SIERRA trial proceeded to BMT, indicating strong efficacy. The company's focus on advancing Iomab-ACT and future milestones suggests a positive outlook for 2021, with expectations of completing enrollment and presenting further trial results.

Actinium Pharmaceuticals, Inc. (NYSE: ATNM) will participate in the BIO CEO & Investor conference from February 16-18, 2021. Actinium's executive team will hold one-on-one meetings with attendees through the BIO One-on-One Partnering™ system. The company focuses on developing Antibody Radiation-Conjugates (ARCs) for treating cancers, including its lead product, I-131 apamistamab (Iomab-B), which is in a pivotal Phase 3 trial for elderly patients with relapsed or refractory acute myeloid leukemia. This trial is over 75% enrolled and has positive preliminary data from prior meetings.

Actinium Pharmaceuticals (NYSE: ATNM) announced its participation in the B. Riley Oncology Investor Conference, scheduled virtually from January 20-21, 2021. Key executives, including Sandesh Seth (Chairman and CEO), Dr. Mark Berger (Chief Medical Officer), and Dr. Dale Ludwig (Chief Scientific Officer), will engage in a moderated discussion led by analyst Justin Walsh. The chat is set for January 21 at 3:30 p.m. ET. Additionally, the executive team is open for one-on-one meetings with attendees.

Actinium Pharmaceuticals (NYSE: ATNM) announced a research collaboration with Astellas Pharma to develop targeted radiotherapies using its Antibody Warhead Enabling (AWE) technology. This partnership aims to utilize Actinium-225 in combination with selected targeting agents from Astellas, contributing to the latter's Rx+ ® initiative for theranostics. Actinium’s AWE platform, protected by a robust intellectual property portfolio, positions the company favorably for this collaboration. Actinium plans to leverage its clinical experience and laboratory capabilities to enhance targeted therapies.

Actinium Pharmaceuticals (ATNM) announced positive interim results from the pivotal Phase 3 SIERRA study for Iomab-B, designed for bone marrow transplant conditioning in older patients with relapsed or refractory AML. The independent Data Monitoring Committee recommended the trial continue, as 100% of patients receiving Iomab-B proceeded to transplant versus 16% in the control arm. Safety data presented at the ASH 2020 Annual Meeting indicated lower rates of serious adverse events in the Iomab-B group. The trial aims to complete enrollment of 150 patients, with over 75% already enrolled.

Actinium Pharmaceuticals (NYSE: ATNM) participated in the virtual Targeted Radiopharmaceuticals Summit from December 8-10, 2020. CEO Sandesh Seth highlighted the company's leadership in targeted radiotherapy and provided updates on its promising clinical programs for Acute Myeloid Leukemia (AML), particularly Iomab-B and Actimab-A. The company aims to leverage its proprietary AWE technology platform for novel targeted therapies. Notably, the pivotal Phase 3 SIERRA trial for Iomab-B is over 75% enrolled, with significant safety data previously presented at major oncology meetings.

Actinium Pharmaceuticals (NYSE: ATNM) announced promising results for its Actimab-A and venetoclax combination therapy in a Phase 1 trial for relapsed or refractory Acute Myeloid Leukemia (AML). Presented at the ASH annual meeting, data indicated one patient achieved a complete remission after the first cycle, with no significant toxicity reported. The trial has progressed to the second dose cohort, reinforcing Actinium's clinical development strategy aimed at enhancing therapeutic efficacy while minimizing side effects.

Actinium Pharmaceuticals (NYSE: ATNM) presented interim data from its pivotal Phase 3 SIERRA trial in relapsed or refractory Acute Myeloid Leukemia at the ASH annual meeting. With 75% patient enrollment, 100% of 49 patients receiving Iomab-B proceeded to Bone Marrow Transplant (BMT), compared to 16% in the control arm. Among those who crossed over from the control group, 100% also proceeded to BMT. The trial shows a durable Complete Remission potential of 77% in the Iomab-B arm versus 12% in the control, highlighting Iomab-B's effectiveness in older, at-risk patients.

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) announced promising safety data from its pivotal Phase 3 SIERRA trial of Iomab-B for treating relapsed or refractory Acute Myeloid Leukemia (R/R AML), presented at the 2020 ASH annual meeting. Data from 110 patients indicated that Iomab-B significantly reduces the rates of sepsis, febrile neutropenia, mucositis, and non-relapse transplant-related mortality compared to traditional therapies. Actinium remains optimistic about Iomab-B's effectiveness leading into the upcoming ad hoc interim analysis for SIERRA, with 75% patient enrollment.